Literature DB >> 17311689

Complications of thoracic computed tomography-guided fiducial placement for the purpose of stereotactic body radiation therapy.

Shadi Yousefi1, Brian T Collins, Cristina A Reichner, Eric D Anderson, Carlos Jamis-Dow, Gregory Gagnon, Shakun Malik, Blair Marshall, Thomas Chang, Filip Banovac.   

Abstract

PURPOSE: This study examined the complication rates associated with percutaneous fiducial placement for the purpose of stereotactic body radiation therapy of primary and metastatic lung neoplasms. PATIENTS AND METHODS: This is a retrospective review of computed tomography (CT) scans and follow-up chest radiographs of 48 consecutive patients who underwent CT-guided percutaneous fiducial placement. The effect of age, sex, number of fiducials placed, and performance of a concomitant biopsy on the complication rates were assessed.
RESULTS: Of 48 patients with a total of 221 fiducials placed, 16 (33%) had a procedure-related pneumothorax. There was no significant difference in pneumothorax rate based on age (P = 0.16), sex (P > 0.99), and number of fiducials placed (P = 0.21). Overall, 6 of 48 patients (12.5%) required a thoracostomy tube. Performance of a concomitant core needle biopsy at the time of fiducial placement was associated with pneumothorax rates of 64% compared with 26% without biopsies (P = 0.03). Postprocedural CT demonstrated hemorrhage in 9 patients (19%). Two patients had hemoptysis; one required admission. Patients' age, sex, number of fiducials placed, and performance of concomitant biopsy had no statistically significant implications on parenchymal hemorrhage incidence.
CONCLUSION: Approximately one third of the patients develop a pneumothorax during CT-guided fiducial placement. Most are asymptomatic and do not require a thoracostomy. A concurrent biopsy at the time of fiducial placement is associated with an increased risk of pneumothorax. Hemorrhage occurs but is usually clinically insignificant.

Entities:  

Mesh:

Year:  2007        PMID: 17311689     DOI: 10.3816/CLC.2007.n.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  17 in total

1.  Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy.

Authors:  An-Na Tong; Peng Yan; Guang-Hui Yuan; Xiao-Yan Lv; Hai Gong; Hui Zhao; Yan-Ming Wang
Journal:  Mol Clin Oncol       Date:  2014-12-10

2.  A radiopaque polymer hydrogel used as a fiducial marker in gynecologic-cancer patients receiving brachytherapy.

Authors:  Ryan J Bair; Eric Bair; Akila N Viswanathan
Journal:  Brachytherapy       Date:  2015-10-23       Impact factor: 2.362

Review 3.  Fiducial marker placement for stereotactic body radiation therapy via convex probe endobronchial ultrasound: a case series and review of literature.

Authors:  Benjamin J Seides; John P Egan; Kim D French; Kevin L Kovitz; Neeraj R Desai
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Complications associated with the percutaneous insertion of fiducial markers in the thorax.

Authors:  Nikhil Bhagat; Nicholas Fidelman; Jeremy C Durack; Jeremy Collins; Roy L Gordon; Jeanne M LaBerge; Robert K Kerlan
Journal:  Cardiovasc Intervent Radiol       Date:  2010-07-27       Impact factor: 2.740

5.  Percutaneous thermal ablation for stage IA non-small cell lung cancer: long-term follow-up.

Authors:  Chaitan K Narsule; Praveen Sridhar; Divya Nair; Avneesh Gupta; Roy G Oommen; Michael I Ebright; Virginia R Litle; Hiran C Fernando
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Single Peripheral Lung Metastases.

Authors:  James W Snider; Eric K Oermann; Viola Chen; Jennifer Rabin; Simeng Suy; Xia Yu; Saloomeh Vahdat; Sean P Collins; Filip Banovac; Eric Anderson; Brian T Collins
Journal:  Front Oncol       Date:  2012-06-29       Impact factor: 6.244

7.  CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Stage I Non-Small Cell Lung Cancer.

Authors:  Viola J Chen; Eric Oermann; Saloomeh Vahdat; Jennifer Rabin; Simeng Suy; Xia Yu; Sean P Collins; Deepa Subramaniam; Filip Banovac; Eric Anderson; Brian T Collins
Journal:  Front Oncol       Date:  2012-02-01       Impact factor: 6.244

8.  Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer.

Authors:  Brian T Collins; Saloomeh Vahdat; Kelly Erickson; Sean P Collins; Simeng Suy; Xia Yu; Ying Zhang; Deepa Subramaniam; Cristina A Reichner; Ismet Sarikaya; Giuseppe Esposito; Shadi Yousefi; Carlos Jamis-Dow; Filip Banovac; Eric D Anderson
Journal:  J Hematol Oncol       Date:  2009-01-17       Impact factor: 17.388

9.  Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors.

Authors:  Brian T Collins; Kelly Erickson; Cristina A Reichner; Sean P Collins; Gregory J Gagnon; Sonja Dieterich; Don A McRae; Ying Zhang; Shadi Yousefi; Elliot Levy; Thomas Chang; Carlos Jamis-Dow; Filip Banovac; Eric D Anderson
Journal:  Radiat Oncol       Date:  2007-10-22       Impact factor: 3.481

10.  Minimal Inter-Fractional Fiducial Migration during Image-Guided Lung Stereotactic Body Radiotherapy Using SuperLock Nitinol Coil Fiducial Markers.

Authors:  Yi Rong; Jose G Bazan; Ashley Sekhon; Karl Haglund; Meng Xu-Welliver; Terence Williams
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.